Rise of carbapenem-resistant Enterobactericaeae

June 14, 2018, European Centre for Disease Prevention and Control (ECDC)

Infections with bacteria resistant to carbapenems, a group of highly effective antibiotics, pose a significant threat to patients and healthcare systems in all EU/EEA countries, warns ECDC in a Rapid Risk Assessment.

Resistance to carbapenems has been reported with increasing frequency and geographical spread since the beginning of the 1990s. The global rise of carbapenem in a certain family of bacteria called Enterobacteriaceae, or carbapenem-resistant Enterobactericaeae (CRE), represents a threat to healthcare delivery and patient safety.

"We should be very concerned about the rise in carbapenem resistance in the EU/EEA as there are very few options for the of patients with CRE infections" says Dominique Monnet, Head of ECDC's Antimicrobial Resistance and Healthcare-Associated Infections Programme. "In recent years, the proportions of carbapenem resistance in Klebsiella pneumoniae - a type of Enterobacteriaceae—rapidly increased to high levels in Greece, Italy and Romania. The same could happen to other EU/EEA countries if appropriate measures are not taken. But the spread of CRE can likely be controlled in most countries through the implementation of appropriate prevention and control measures in hospitals and other healthcare settings."

CRE are often a cause of and in hospital settings. Such infections are associated with prolonged hospital stays, high treatment costs, treatment failures and high mortality, primarily due to delays in the administration of effective treatment and the limited availability of treatment options.

Data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) for 2016 show large differences in the national percentages of resistant bloodstream infections caused by Klebsiella pneumonia, ranging from 0% to as high as 67%, depending on the country. Although prevalence is still low in most European countries, Romania, Italy and Greece, with 31%, 34% and 67%, respectively, are among the countries reporting the highest prevalences worldwide.

In general, if the frequency of resistance to an antibiotic is high, it cannot be recommended for empiric treatment anymore due to the risk of failure. In case of CRE infection, there is no good antibiotic alternative for empiric treatment that does not carry serious side effects or other complications.

Introduction of CRE into low-prevalence EU/EEA countries can happen when patients are transferred from an EU Member State with a high level of CRE, or from other countries or regions of the world with high reported levels of CRE, e.g. countries in the eastern and southern Mediterranean regions, the Indian subcontinent and south-east Asia.

Timely and appropriate laboratory investigation and reporting is essential to avoid delays in appropriate treatment and in the implementation of appropriate infection control measures. Strict adherence to control measures and implementation of comprehensive antimicrobial stewardship programmes are key to prevent and control the emergence and spread of CRE, as highlighted in the ECDC rapid risk assessment.

Explore further: Efforts needed to stop the spread of carbapenem-resistant Acinetobacter baumannii

More information: ecdc.europa.eu/en/publications … riaceae-first-update

Related Stories

Efforts needed to stop the spread of carbapenem-resistant Acinetobacter baumannii

December 14, 2016
ECDC's latest risk assessment highlights the need of increased efforts to face this significant threat to patients and healthcare systems in all EU/EEA countries and outlines options to reduce risks through clinical management, ...

Combined resistance to multiple antibiotics: A growing problem in the EU

November 15, 2017
On the occasion of the 10th European Antibiotic Awareness Day, the European Centre for Disease Prevention and Control (ECDC) is releasing its latest EU-wide data on antibiotic resistance, as well as its guidance on prevention ...

Drug resistance genes shared among bacteria in hospitals can be deadly

June 10, 2018
A hospital outbreak of carbapenem-resistant Enterobacteriaceae (CRE) became more worrisome when researchers found resistance genes being shared among unrelated bacteria via plasmids and other mobile genetic elements. This ...

Antibiotic-resistant bacteria found in the US presents a triple threat

June 9, 2018
Researchers from the Emory Antibiotic Resistance Center describe the first strain of carbapenem-resistant, hypermucoviscous Klebsiella pneumoniae exhibiting colistin heteroresistance and enhanced virulence isolated from a ...

Antimicrobial resistance in zoonotic bacteria still high in humans, animals and food

February 27, 2018
Bacteria from humans and animals continue to show resistance to antimicrobials, according to a new report published today by the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control ...

Avoid piperacillin-tazobactam when treating BSI cause by ceftriaxone-resistant pathogens

April 22, 2018
The antibiotic combination treatment piperacillin-tazobactam was significantly less effective than meropenem when treating potentially fatal bloodstream infections (BSI) caused by ceftriaxone-resistant Escherichia coli and ...

Recommended for you

Green leafy vegetables may prevent liver steatosis

December 17, 2018
A larger portion of green leafy vegetables in the diet may reduce the risk of developing liver steatosis, or fatty liver. In a study published in PNAS researchers from Karolinska Institutet in Sweden show how a larger intake ...

Discovery of novel mechanisms that cause migraines

December 17, 2018
Researchers at CNRS, Université Côte d'Azur and Inserm have demonstrated a new mechanism related to the onset of migraine. They found how a mutation that causes dysfunction in a protein which inhibits neuronal electrical ...

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.